<DOC>
	<DOCNO>NCT00612001</DOCNO>
	<brief_summary>RATIONALE : Vaccines make peptide person 's dendritic cell may help body build effective immune response kill tumor cell . PURPOSE : This phase I trial study side effect best dose vaccine therapy treat patient malignant glioma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine dose-limiting toxicity maximum tolerate dose autologous dendritic cell pulse synthetic glioma-associated antigen ( GAA ) peptides patient malignant glioma . - Determine survival , tumor progression , cellular immune response patient treat regimen . OUTLINE : Patients undergo leukapheresis collection peripheral blood mononuclear cell ( PBMC ) . Autologous dendritic cell ( DC ) prepare autologous PBMC expose sargramostim ( GM-CSF ) interleukin-4 ( IL-4 ) , mature cytokine cocktail , pulse synthetic glioma-associated antigen ( GAA ) peptide . Cohorts patient receive escalate dos GAA peptide-pulsed autologous dendritic cell vaccine maximum tolerate dose determine . After completion study treatment , patient follow every 2 month 1 year .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Histologically confirm diagnosis 1 follow malignant glioma : Anaplastic astrocytoma Glioblastoma multiforme Oligodendroglioma Oligoastrocytoma WHO grade III IV disease Newly diagnose recurrent disease Bidimensionally measurable disease contrastenhancing MRI Surgically accessible tumor resection indicate Previously treat planning undergo treatment conventional external beam radiotherapy HLAA*201 positive Karnofsky performance status 60100 % Life expectancy ≥ 8 week Hemoglobin ≥ 10 g/dL Absolute granulocyte count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ SGOT SGPT ≤ 2 time normal Alkaline phosphatase ≤ 2 time normal Bilirubin ≤ 1.5 mg/dL BUN ≤ 1.5 time normal OR creatinine ≤ 1.5 time normal Negative pregnancy test Fertile patient must use effective contraception Hepatitis B negative Hepatitis C negative HIV negative Syphilis serology negative Afebrile active infection immunodeficiency autoimmune disease may exacerbate immunotherapy , include follow : Rheumatoid arthritis Systemic lupus erythematosus Vasculitis Polymyositisdermatomyositis Scleroderma Multiple sclerosis Juvenileonset insulindependent diabetes allergy study agent underlying condition would contraindicate study therapy concurrent severe unstable medical condition would preclude give informed consent psychiatric condition would preclude study participation give informed consent malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , localize prostate cancer , carcinoma situ cervix prior chemotherapy ( 6 week nitrosoureas ) within last 4 week start treatment concurrent corticosteroid within 2 week prior treatment radiotherapy within 2 week prior treatment systemic antibiotic within 72 hour prior treatment prior organ allograft antihistamine therapy within 5 day administration study vaccine chemotherapy 4 week administration study vaccine adjuvant therapy 4 week administration study vaccine concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult mixed glioma</keyword>
</DOC>